金安國紀(002636.SZ):全資子公司再次通過高新技術企業認定
格隆匯3月23日丨金安國紀(002636.SZ)公佈,公司的全資子公司杭州國紀已取得浙江省科學技術廳、浙江省財政廳、國家税務總局浙江省税務局聯合頒發的《高新技術企業證書》,證書編號:GR201933003043,發證時間:2019年12月4日,有效期:三年。
根據相關規定,杭州國紀通過高新技術企業重新認定後連續三年(2019年-2021年)將繼續享受高新技術企業的相關優惠政策,即按15%的税率繳納企業所得税。此次取得《高新技術企業證書》後,杭州國紀將向當地税務部門提出申請,在證書有效期內享受國家相關的優惠政策。上述税收優惠政策的享受不會對公司2019年度的經營業績產生影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.